Thomas Stauch: ITP Therapeutics Enter a New Era of Targeted Treatment
Thomas Stauch, Founder of Hematology and Oncology Practice in Jena, Consultant Physician at Jena University Hospital, shared a post on LinkedIn:
“Always great to listen to David Kuter speaking about ITP.
His work has shaped our understanding of immune thrombocytopenia for decades and has influenced the care of countless patients worldwide.
At EHA 2026, Prof. Kuter presented the final long-term extension results of the LUNA 3 study evaluating rilzabrutinib in persistent and chronic ITP.
Beyond the data itself, it is inspiring to see a true pioneer continue to drive innovation and challenge our thinking in a field that has evolved tremendously over the last years.
From corticosteroids and splenectomy to TPO receptor agonists, SYK inhibition, BTK inhibition, FcRn blockade, complement inhibition, and emerging immune-modulating approaches, the therapeutic landscape of ITP has never been more dynamic.
Much of this progress has been accompanied, influenced, or inspired by leaders such as Prof. Kuter.
Thank you for your lifelong dedication to advancing ITP research and improving the lives of our patients.”
Stay updated with Hemostasis Today.
-
Sep 3, 2026, 20:33Jennifer Weinstein: Happy to Share Our New Work on the Patient Experience in VWD at the NBDF Conference
-
Sep 3, 2026, 20:31Guillaume Courbon: New Publication on Erythroid-Produced FGF23 and Its Role in Anemia
-
Sep 3, 2026, 20:30Phuong Khanh Morrow: FDA Approval Marks an Important Step Forward for the PV Community
-
Sep 3, 2026, 20:29Sarah Robins: Happy to Share This Portrait Film I Voiced for the NNHHF
-
Sep 3, 2026, 20:27Mireille Muller: Europe Needs More Plasma Donors
-
Sep 3, 2026, 17:54Tareq Abadl: Extravascular Hemolysis The High-Yield Guide
-
Sep 3, 2026, 17:48Isabel Sá: Starting a New Chapter as a Clinical Scientist in Molecular Genetics and Haematology
-
Sep 3, 2026, 17:40Chiwoo Oh: AS01B Adjuvant and Long-Term Immune Reprogramming After Shingrix Vaccination
-
Sep 3, 2026, 17:35Key Developments in Transfusion Medicine and Biotherapies in 2025 – AABB